Third Rock Ventures has topped the 2025 ranking of biotech VC firms, delivering the highest returns on investments among its peers.
Why it matters: The ranking offers a rare glimpse into the financial successes and shortcomings of prominent biotech venture firms, highlighting the challenges and opportunities in the evolving biotech investment landscape.
The details:
- Third Rock has routinely tripled investors’ money, returning a median of $3.58 for every dollar invested by pension funds or university endowments.
- The firm’s impressive performance is based on its first three funds, raised between 2007 and 2013.
- Third Rock has financed several successful companies, including Blueprint Medicines, MyoKardia, and Thrive Earlier Detection Corp.
- In June, MyoKardia, a company in which Third Rock first invested in 2011, was acquired for $9.1 billion.
However, the biotech investment landscape has become increasingly challenging, with recent years seeing one of the worst markets for biotech startups and investors.
The challenges:
- The federal government has cut funding for scientific research, jeopardizing experiments that could lead to new biotech startups.
- Biotech’s share of the overall venture capital market has plummeted, falling from 19% in 2012 to just 4% in the first quarter of 2025.
- Many in the industry debate the scalability of large funds, arguing that smaller funds are more likely to deliver higher returns.
“Biotech venture is a game of probabilities. Failure is a constant — of drug programs and companies alike. It’s like gravity, a constant pull downward,” wrote Bruce Booth, a partner at Atlas Venture.
What’s next: While Third Rock Ventures has demonstrated strong performance and ambitious goals, the evolving market conditions and size of recent funds pose new challenges for the firm and the broader biotech venture capital landscape.